Table 4.
Pharmacoprophylaxis use and post-ERCP amylase measurement (subgrouped by PPS vs non-PPS use)
| Overall | PPS users | Non-PPS users | ||||
|---|---|---|---|---|---|---|
| Pharmacoprophylaxis use | Yes | No | Yes | No | Yes | No |
| NSAID | 72 (34.2%) | 136 (65.4%) | 53 (47.3%) | 59 (52.7%) | 18 (19.1%) | 76 (80.9%) |
| Antibiotics | 41 (20.6%) | 158 (79.4%) | 17 (17.2%) | 82 (82.8%) | 24 (24.2%) | 75 (75.8%) |
| Intravenous fluids | 25 (13.2%) | 165 (86.8%) | 16 (16.2%) | 83 (83.8%) | 9 (10.0%) | 81 (90.0%) |
| Octreotide | 3 (1.6%) | 185 (98.4%) | 0 (0%) | 97 (100%) | 3 (3.3%) | 87 (96.7%) |
| Post-ERCP amylase measurement | 13 (6.0%) | 205 (94.0%) | 6 (5.3%) | 108 (94.7%) | 7 (6.9%) | 94 (93.1%) |
The overall number of respondents included respondents who did not declare whether they used PPS or not.
ERCP, endoscopic retrograde cholangiopancreatography; NSAID, non-steroidal anti-inflammatory drug; PPS, prophylactic pancreatic stent.